AstraZeneca investors questioned the benefits of a potential Bristol Myers Squibb merger despite expected gains in the US market and cost synergies.
Important
AstraZeneca Shares Sink 7% On $400 Billion Bristol Myers Buyout Talks
AstraZeneca investors questioned the benefits of a potential Bristol Myers Squibb merger despite expected gains in the US market and cost synergies. Source: Read the original article on www.ndtvprofit.com